首页> 外文期刊>Antiviral Research >The role of helioxanthin in inhibiting human hepatitis B viral replication and gene expression by interfering with the host transcriptional machinery of viral promoters.
【24h】

The role of helioxanthin in inhibiting human hepatitis B viral replication and gene expression by interfering with the host transcriptional machinery of viral promoters.

机译:硫氧黄质通过干扰病毒启动子的宿主转录机制,在抑制人类乙型肝炎病毒复制和基因表达中的作用。

获取原文
获取原文并翻译 | 示例
       

摘要

A non-nucleosidic compound, Helioxanthin (HE-145), was found to suppress HBV gene expression and replication in HCC cells. To understand the molecular mode of action of HE-145 on HBV gene expression, the effects of HE-145 on four viral promoter activities using luciferase as a reporter were examined. It was found that HE-145 selectively suppresses surface antigen promoter II (SPII) and core promoter (CP) but has no effect on surface antigen promoter I (SPI) or promoter for X gene (Xp). The suppressive effects of HE-145 on either SPII or CP activity is liver-specific, since no suppressive activity of HE-145 was observed when CP or SPII promoter activity was assayed in non-liver cells such as HeLa or 293T. To examine the mode of action of HE-145, EMSA analysis revealed that HE-145 decreased the DNA-binding activity of nuclear extract of HepA2 cells to specific cis element of HBV promoter for core antigen, including peroxisome proliferator-activated receptors (PPARs), PPARs binding site (PPRE), alpha-fetoprotein transcription factor (FTF), and Sp1. Ectopic expression of PPAR gamma or HNF4 alpha partially reversed the HE-145-mediated suppression of HBV RNA. Therefore, HE-145 may represent a novel class of anti-HBV agents which selectively modulate transcriptional machinery of human liver cells to suppress HBV gene expression and replication.
机译:发现了一种非核苷化合物,Helioxanthin(HE-145),可以抑制HBV基因在HCC细胞中的表达和复制。为了了解HE-145对HBV基因表达的分子作用方式,使用荧光素酶作为报告基因,研究了HE-145对四种病毒启动子活性的影响。发现HE-145选择性抑制表面抗原启动子II(SPII)和核心启动子(CP),但对表面抗原启动子I(SPI)或X基因启动子(Xp)没有影响。 HE-145对SPII或CP活性的抑制作用是肝脏特异性的,因为在非肝细胞(如HeLa或293T)中检测CP或SPII启动子活性时,未观察到HE-145的抑制活性。为了检查HE-145的作用方式,EMSA分析显示HE-145降低了HepA2细胞核提取物对HBV启动子特异的顺式元件对核心抗原(包括过氧化物酶体增殖物激活受体(PPAR))的DNA结合活性,PPAR结合位点(PPRE),甲胎蛋白转录因子(FTF)和Sp1。 PPARγ或HNF4α的异位表达部分逆转了HE-145介导的HBV RNA抑制。因此,HE-145可能代表一类新型的抗HBV药物,可选择性调节人肝细胞的转录机制以抑制HBV基因的表达和复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号